Judge Sends FTC Case Over Syngenta Crop Chemical Rebates to a Jury Trial

A federal judge in North Carolina has refused to end the Federal Trade Commission's antitrust case against Syngenta, the crop protection company whose loyalty rebate program the government says kept cheaper generic pesticides away from American farmers. In an opinion and order issued on October 22, 2026, Judge Thomas D. Schroeder of the US District Court for the Middle District of North Carolina denied Syngenta's motion for summary judgment, according to the FTC's case page and reporting by Bloomberg Law and Wolters Kluwer's Antitrust Law Daily.

The ruling does not decide who is right. It decides that the dispute is serious enough, and the evidence contested enough, that a jury should hear it.

What the Case Is About

The FTC and a group of state attorneys general sued Syngenta and Corteva in 2022. They alleged that each company ran a post-patent loyalty program that paid distributors to limit their purchases of generic versions of pesticide ingredients once patents had expired.

Syngenta's program is known as Key Active Ingredients, or "Key AI." Under it, distributors earned rebates for buying a high share of certain active ingredients from Syngenta. The government says that structure made it costly for distributors to carry generic alternatives, which kept prices higher for growers. The claims include unfair competition under Section 5 of the FTC Act, Section 3 of the Clayton Act, Sections 1 and 2 of the Sherman Act and consumer protection laws in several states.

Syngenta denies wrongdoing. It argued that the rebates lowered prices for growers, that barriers to entry are low and that generic makers have in fact entered and grown in these markets.

What the Judge Decided

According to the Antitrust Law Daily summary of the opinion, the court made several findings that all point the same way: toward trial.

The price test did not apply. Syngenta asked the court to use a price-cost test, which asks whether a discount pushes prices below cost. The court declined, finding evidence that price was not the main way the program excluded rivals. It pointed to evidence that Syngenta ended a contract with a distributor that missed Key AI thresholds and that other distributors feared being cut off.

The market could be defined by ingredient. Syngenta argued the relevant market should include any product that does the same job for a farmer. The government defined each market by a single active ingredient. The court found enough evidence, including Syngenta's own tracking of sales and market share by ingredient, for a jury to accept the government's approach.

Foreclosure and harm are questions for the jury. Syngenta acknowledged that its Key AI distributors controlled at least 60 percent of crop protection product sales, according to the summary. Syngenta pointed out that generics had captured up to 36 percent of the market. The court called that figure relevant but not decisive and said a jury could find substantial foreclosure and higher prices for growers.

The court also kept the state law claims alive and refused to dismiss two Syngenta parent entities from the case.

Why Summary Judgment Matters

Summary judgment lets a court end a case without a trial when the key facts are not genuinely disputed. A judge at this stage does not weigh credibility or choose between competing stories. The question is only whether a reasonable jury could rule for the other side.

That is why a denial is not a loss on the merits for Syngenta. It means the company's defenses, including its evidence that generics grew and that farmers benefited from rebates, will be tested in front of a jury rather than resolved on paper. In the court's words as quoted by Antitrust Law Daily, whether a jury would agree on the disputed points "must remain for trial."

Corteva Settled First

The case began with two defendants. On September 25, 2026, the FTC and the states filed an agreed order settling with Corteva. According to the FTC, the order requires Corteva to dismantle its active-ingredient-based loyalty programs and bars it for ten years from conditioning payments on customers buying a high share of an ingredient from Corteva or limiting their purchases of generics. Antitrust Law Daily reported that Corteva, without admitting wrongdoing, also agreed to pay $35 million into a fund for the states. Court approval of that settlement was still pending when the Syngenta ruling issued.

What Comes Next

No trial date was reported with the ruling. Syngenta can continue to press its defenses at trial, and the parties remain free to settle, as Corteva did. For farmers, distributors and generic makers, the case is now one of the most closely watched tests of how loyalty rebates are treated under US antitrust law. Court Magazine will follow the case as it moves toward trial.